E-therapeutics Plc
E-therapeutics Plc (ETXPF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
etxpf · pe ratio · data through Jan 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for E-therapeutics Plc (ETXPF) measures how much investors pay for each dollar of the company's trailing earnings. ETXPF's current PE ratio of N/A is calculated by dividing its stock price of $0.13 by its TTM earnings per share of -$0.02.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-01-31
PE Ratio History
2007 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
E-therapeutics PlcYou ETXPF | $76M | N/A | — | -$0.02 |
 Biostage, Inc. BSTG | $58M | N/A | — | -$0.42 |
 Ecofibre Limited EOFBY | $74M | N/A | — | -$0.12 |
 Herantis Pharma Oyj HRPMF | $59M | N/A | — | -$0.24 |
 Karolinska Development AB (publ) KDEVF | $69M | 129.97x | — | $0.02 |
 Mind Cure Health Inc. MCURF | $87M | N/A | — | -$0.15 |
 Mindset Pharma Inc. MSSTF | $55M | N/A | — | -$0.18 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-01-31Latest FY2025 | — | $-0.02 | — | |
2024-01-31 FY2024 | — | $-0.02 | — | |
2023-01-31 FY2023 | — | $-0.02 | — | |
2022-01-31 FY2022 | — | $-0.02 | — | |
2021-01-31 FY2021 | — | $-0.01 | — | |
2020-01-31 FY2020 | — | $-0.01 | — | |
2019-01-31 FY2019 | — | $-0.02 | — | |
2018-01-31 FY2018 | — | $-0.03 | — | |
2017-01-31 FY2017 | — | $-0.06 | — | |
2016-01-31 FY2016 | — | $-0.05 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for E-therapeutics Plc (ETXPF) measures how much investors pay for each dollar of the company's trailing earnings. ETXPF's current PE ratio of N/A is calculated by dividing its stock price of $0.13 by its TTM earnings per share of -$0.02.
Frequently asked questions
ETXPF pe ratio · 6 questionsETXPF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.13 and TTM EPS of -$0.02. Data sourced from Financial Modeling Prep via ETXPF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · E-therapeutics Plc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09